(secondQuint)Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer.

 The multicenter randomized phase II study will enroll a target of approximately 150 first-line patients with metastatic CRC.

 EGFR expression is not required for study entry, however, the EGFR status will be measured retrospectively.

 Patients are randomized to Arm A or Arm B.

 Arm A: FOLFOX 6 in combination with cetuximab Arm B: FOLFIRI in combination with cetuximab.

 Both efficacy and safety data will be collected.

 The investigators will assess response to treatment at 6 weeks, 12 weeks and thereafter every 12 weeks based on imaging Following permanent treatment cessation (stop of all study treatments) patients will be followed-up for.

.

 Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer@highlight

In Patients with metastatic colorectal cancer the following treatments first-line Folfiri+Cetuximab first-line Folfox6 + Cetuximab will be concerning efficacy and safety.

 The trial compares Folfiri + Cetuximab and Folfox6 + Cetuximab concerning efficacy and safety as first